Effects of lanreotide Autogel primary therapy on symptoms and quality-of-life in acromegaly

To evaluate the effects of lanreotide Autogel on patient-reported outcomes and association with biochemical control, using PRIMARYS data. PRIMARYS was a 1-year, open-label study of lanreotide Autogel (Depot in USA) 120 mg every 4 weeks in 90 treatment-naïve patients with acromegaly. Symptoms were as...

Descripción completa

Detalles Bibliográficos
Autores: Caron, Philippe J., Bevan, John S., Petersenn, Stephan, Houchard, Aude|||0000-0001-6248-8986, Sert, Caroline, Webb, Susan|||0000-0001-7052-6436
Tipo de recurso: artículo
Fecha de publicación:2015
País:España
Institución:Universitat Autònoma de Barcelona
Repositorio:Dipòsit Digital de Documents de la UAB
Idioma:inglés
OAI Identifier:oai:ddd.uab.cat:185474
Acceso en línea:https://ddd.uab.cat/record/185474
https://dx.doi.org/urn:doi:10.1007/s11102-015-0693-y
Access Level:acceso abierto
Palabra clave:Acromegaly
Lanreotide Autogel
Quality of life
Symptoms
id ES_9a655ea20fc47dfd4498f0e4fda6efbf
oai_identifier_str oai:ddd.uab.cat:185474
network_acronym_str ES
network_name_str España
repository_id_str
spelling Effects of lanreotide Autogel primary therapy on symptoms and quality-of-life in acromegalydata from the PRIMARYS studyCaron, Philippe J.Bevan, John S.Petersenn, StephanHouchard, Aude|||0000-0001-6248-8986Sert, CarolineWebb, Susan|||0000-0001-7052-6436AcromegalyLanreotide AutogelQuality of lifeSymptomsTo evaluate the effects of lanreotide Autogel on patient-reported outcomes and association with biochemical control, using PRIMARYS data. PRIMARYS was a 1-year, open-label study of lanreotide Autogel (Depot in USA) 120 mg every 4 weeks in 90 treatment-naïve patients with acromegaly. Symptoms were assessed using Patient-assessed Acromegaly Symptom Questionnaire (PASQ) and health-related quality of life (HRQoL) using the AcroQoL questionnaire. Correlations between PASQ and AcroQoL scores, and between PASQ/AcroQoL and growth hormone (GH)/insulin-like growth factor-1 (IGF-1) levels were also evaluated (post hoc). Acromegaly symptoms and HRQoL significantly improved from week 12 to week 48, with modest correlations at week 48 between PASQ total score (R = -0.55, p < 0.0001) and AcroQoL global and physical scores (R = -0.67, p < 0.0001). Approximately 60 % of patients achieved a minimal important difference (MID; improvement.Universitat Autònoma de Barcelona 22015-01-0120152015-01-01Articlehttp://purl.org/coar/resource_type/c_6501VoRhttp://purl.org/coar/version/c_970fb48d4fbd8a85info:eu-repo/semantics/articleapplication/pdfhttps://ddd.uab.cat/record/185474https://dx.doi.org/urn:doi:10.1007/s11102-015-0693-yreponame:Dipòsit Digital de Documents de la UABinstname:Universitat Autònoma de BarcelonaInglésengopen accesshttp://purl.org/coar/access_right/c_abf2Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original.https://creativecommons.org/licenses/by/4.0/info:eu-repo/semantics/openAccessoai:ddd.uab.cat:1854742026-06-06T12:50:31Z
dc.title.none.fl_str_mv Effects of lanreotide Autogel primary therapy on symptoms and quality-of-life in acromegaly
data from the PRIMARYS study
title Effects of lanreotide Autogel primary therapy on symptoms and quality-of-life in acromegaly
spellingShingle Effects of lanreotide Autogel primary therapy on symptoms and quality-of-life in acromegaly
Caron, Philippe J.
Acromegaly
Lanreotide Autogel
Quality of life
Symptoms
title_short Effects of lanreotide Autogel primary therapy on symptoms and quality-of-life in acromegaly
title_full Effects of lanreotide Autogel primary therapy on symptoms and quality-of-life in acromegaly
title_fullStr Effects of lanreotide Autogel primary therapy on symptoms and quality-of-life in acromegaly
title_full_unstemmed Effects of lanreotide Autogel primary therapy on symptoms and quality-of-life in acromegaly
title_sort Effects of lanreotide Autogel primary therapy on symptoms and quality-of-life in acromegaly
dc.creator.none.fl_str_mv Caron, Philippe J.
Bevan, John S.
Petersenn, Stephan
Houchard, Aude|||0000-0001-6248-8986
Sert, Caroline
Webb, Susan|||0000-0001-7052-6436
author Caron, Philippe J.
author_facet Caron, Philippe J.
Bevan, John S.
Petersenn, Stephan
Houchard, Aude|||0000-0001-6248-8986
Sert, Caroline
Webb, Susan|||0000-0001-7052-6436
author_role author
author2 Bevan, John S.
Petersenn, Stephan
Houchard, Aude|||0000-0001-6248-8986
Sert, Caroline
Webb, Susan|||0000-0001-7052-6436
author2_role author
author
author
author
author
dc.contributor.none.fl_str_mv Universitat Autònoma de Barcelona
dc.subject.none.fl_str_mv Acromegaly
Lanreotide Autogel
Quality of life
Symptoms
topic Acromegaly
Lanreotide Autogel
Quality of life
Symptoms
description To evaluate the effects of lanreotide Autogel on patient-reported outcomes and association with biochemical control, using PRIMARYS data. PRIMARYS was a 1-year, open-label study of lanreotide Autogel (Depot in USA) 120 mg every 4 weeks in 90 treatment-naïve patients with acromegaly. Symptoms were assessed using Patient-assessed Acromegaly Symptom Questionnaire (PASQ) and health-related quality of life (HRQoL) using the AcroQoL questionnaire. Correlations between PASQ and AcroQoL scores, and between PASQ/AcroQoL and growth hormone (GH)/insulin-like growth factor-1 (IGF-1) levels were also evaluated (post hoc). Acromegaly symptoms and HRQoL significantly improved from week 12 to week 48, with modest correlations at week 48 between PASQ total score (R = -0.55, p < 0.0001) and AcroQoL global and physical scores (R = -0.67, p < 0.0001). Approximately 60 % of patients achieved a minimal important difference (MID; improvement.
publishDate 2015
dc.date.none.fl_str_mv 2
2015-01-01
2015
2015-01-01
dc.type.none.fl_str_mv Article
http://purl.org/coar/resource_type/c_6501
VoR
http://purl.org/coar/version/c_970fb48d4fbd8a85
dc.type.openaire.fl_str_mv info:eu-repo/semantics/article
format article
dc.identifier.none.fl_str_mv https://ddd.uab.cat/record/185474
https://dx.doi.org/urn:doi:10.1007/s11102-015-0693-y
url https://ddd.uab.cat/record/185474
https://dx.doi.org/urn:doi:10.1007/s11102-015-0693-y
dc.language.none.fl_str_mv Inglés
eng
language_invalid_str_mv Inglés
language eng
dc.rights.none.fl_str_mv open access
http://purl.org/coar/access_right/c_abf2
https://creativecommons.org/licenses/by/4.0/
dc.rights.openaire.fl_str_mv info:eu-repo/semantics/openAccess
rights_invalid_str_mv open access
http://purl.org/coar/access_right/c_abf2
https://creativecommons.org/licenses/by/4.0/
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.source.none.fl_str_mv reponame:Dipòsit Digital de Documents de la UAB
instname:Universitat Autònoma de Barcelona
instname_str Universitat Autònoma de Barcelona
reponame_str Dipòsit Digital de Documents de la UAB
collection Dipòsit Digital de Documents de la UAB
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869414383868706816
score 15,300719

Similares en LA Referencia